Eric Schmidt, an analyst with Cowen & Co., said Amgen's (AMGN) track record in the first two quarters has been inconsistent, lurching from a lousy first quarter to a good second quarter. He said he would "feel good" if the company hits $3.8 billion on the revenue side in its earnings report.

Amgen has rallied about 27% to 58.50, since its lows in March. As sales of denosumab start to climb, the stock could command a higher multiple -- and, eventually, a price of 78.

good company

top notch bio tech makes money, great r&d, strong product pipeline

Amgen (AMGN) reports a good number, and it goes up again! I mean, how many times can you take a stock up on the same news? You can when a stock is simply depressed way beyond where it should have gone.

I’d get out of Amgen (AMGN) ahead of August 13th, counsels Joe Terranova; that's when they go before the FDA.

I think Amgen’s (AMGN) upgrade was all about their new cancer drug, muses Joe Terranova. I think it’s a great stock. Najarian said the $65 price target for company, with 10 drugs in the final stage of Phase 3 tests, is probably right

Solid drug company that could provide manufacturing for cheap pharmaceuticals. However, this stock could be in trouble if it fails to adjust to Obama's policies.

I’d look at Amgen (AMGN), adds Joe Terranova. I just got stopped out of my trade but I think it’s the bottom.

Money maker

never a winning trade out of 5 but all small losses

It's killing me

down trend

took a dive

troubled future, problemic present, nothing in pipeline, existing products under siege

to much promise and can not deliver

lost losts of $$$'s

didn't pay attention while it fell $30 share

Recommendation that's gone nowhere

don't understand the field